Newsroom | 20117 results

FOSTER CITY, California e WILMINGTON, Delaware--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) e Incyte (Nasdaq: INCY) oggi hanno annunciato che la Food and Drug Administration (FDA) statunitense ha approvato le compresse di Atebrioz™ (zilurgisertib) per ridurre il volume della nuova ossificazione eterotopica totale in pazienti adulti e pediatrici di almeno 12 anni di età affetti da fibrodisplasia ossificante progressiva. Il testo originale del presente annuncio, redatto nella ling...

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) en Incyte (Nasdaq:INCY) hebben vandaag bekendgemaakt dat de Amerikaanse Food and Drug Administration (FDA) Atebrioz™ (zilurgisertib) tabletten heeft goedgekeurd voor het verminderen van het totale volume aan nieuwe heterotope ossificatie (HO) bij volwassen en pediatrische patiënten van 12 jaar en ouder met fibrodysplasia ossificans progressiva (FOP). Deze bekendmaking is officieel geldend in de or...

FOSTER CITY, Californie et WILMINGTON, Delaware--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq : MIRM) et Incyte (Nasdaq : INCY) ont annoncé aujourd’hui que la Food and Drug Administration (FDA) américaine avait approuvé les comprimés d’Atebrioz™ (zilurgisertib) pour réduire le volume total des nouvelles ossifications hétérotopiques (HO) chez les patients adultes et pédiatriques âgés de 12 ans et plus atteints de fibrodysplasie ossifiante progressive (FOP). La posologie recommandée d’Ate...

FOSTER CITY, Kalifornien und WILMINGTON, Delaware--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) und Incyte (Nasdaq: INCY) gaben heute bekannt, dass die US-amerikanische Food and Drug Adminstration (FDA) die Zulassung für Atebrioz™ (Zilurgisertib) Tabletten erteilt hat, die das Volumen der gesamten neuen heterotopischen Ossifikation (HO) bei erwachsenen und pädiatrischen Patienten mit Fibrodysplasia ossificans progressiva (FOP) im Alter von über 12 Jahren reduzieren sollen. Die em...

FOSTER CITY (California) y WILMINGTON (Delaware)--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) e Incyte (Nasdaq:INCY) anunciaron hoy que la Administración de Alimentos y Medicamentos (FDA) de los Estados Unidos aprobó las tabletas de Atebrioz™ (zilurgisertib) para reducir el volumen de nueva osificación heterotópica (HO) total en pacientes adultos y pediátricos desde 12 años con fibrodisplasia osificante progresiva (FOP). El comunicado en el idioma original es la versión oficial y...

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva...

AURORA, Colo.--(BUSINESS WIRE)--RefinedScience today announced a multi-institutional agreement that puts the Marsico Pancreatic Cancer Initiative on track to become the world’s largest multimodal single-cell pancreatic ductal adenocarcinoma (PDAC) dataset by the end of 2026, with contracted and partnered access to more than 2,000 consented pancreatic cancer samples from leading academic and industry sources. Pancreatic cancer is among the deadliest major cancers, in large part because the disea...

LOS ANGELES--(BUSINESS WIRE)--ASTRO 2026 presentations demonstrate role of genetics in predicting adverse events and response from radiation treatment....

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis...

LAWRENCE, Kan.--(BUSINESS WIRE)--Endpoints News Announces the 2026 Winners of the Endpoints 11 Awards, showcasing biotech’s most exciting startups...